Correspondence on ‘Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis’
| Autor: | Eleftherios Pelechas, Alexandros A. Drosos, A N Georgiadis, Paraskevi V. Voulgari |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
musculoskeletal diseases
0301 basic medicine medicine.medical_specialty Immunology Arthritis Disease General Biochemistry Genetics and Molecular Biology Etanercept 03 medical and health sciences 0302 clinical medicine Rheumatology Internal medicine medicine Immunology and Allergy Risk factor skin and connective tissue diseases 030203 arthritis & rheumatology medicine.diagnostic_test business.industry Magnetic resonance imaging Early rheumatoid arthritis medicine.disease 030104 developmental biology Rheumatoid arthritis Methotrexate business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. :annrheumdis-2021 |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2021-219891 |
| Popis: | We have read with interest the article by Plein et al that has been published recently in the Annals of Rheumatic Diseases. The article deals with the cardiovascular (CV) effects of biological disease-modifying antirheumatic drugs (DMARDs) versus conventional synthetic (cs) DMARD therapy in early naive rheumatoid arthritis (RA) patients.1 The authors compared etanercept (ETN) plus methotrexate (MTX) treatment versus MTX treat-to-target (TT) approach in patients with early RA (ERA), without CV disease and maximum one traditional risk factor. All patients underwent CVMR at baseline and after 1 and 2 years thereafter. At diagnosis, patients with ERA had reduced vascular distensibility, evidence of myocardial fibrosis and reduced left ventricular mass. The study revealed the presence of CV damage … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|